Glioma Clinical Trials in New York, New York

13 studies are recruiting for glioma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

   The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following ques…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   30 in total

   Run by

   Black Diamond Therapeutics, Inc.

   See if you can join NCT07326566 on ClinicalTrials.gov

2. A Study of Mirdametinib in People With Central Nervous System Tumors

   The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07539441 on ClinicalTrials.gov

3. Glioma Developmental and HyperActive Ras Tumor (DHART) Board

   This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific d…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05489783 on ClinicalTrials.gov

4. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

   This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   61 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT05303519 on ClinicalTrials.gov

5. Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

   A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   New York Presbyterian Hospital-Columbia University Medical Center, New York, New York

   Locations

   2 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT07486713 on ClinicalTrials.gov

6. A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

   This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high gra…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   3 in total

   Run by

   Tetragon Biosciences Ltd

   See if you can join NCT07464925 on ClinicalTrials.gov

7. Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

   This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05188508 on ClinicalTrials.gov

8. A Study of 177Lu-PSMA-617 in People With Gliomas

   The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07223034 on ClinicalTrials.gov

9. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

   This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lenox Hill Brain Tumor Center, New York, New York

   Run by

   Northwell Health

   See if you can join NCT05979064 on ClinicalTrials.gov

10. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

    Locations

    23 in total

    Run by

    Nested Therapeutics, Inc

    See if you can join NCT06326411 on ClinicalTrials.gov

11. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

    This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

    Stage

    Phase 3

    Ages

    Any age

    Site

    Children's Hospital at Montefiore Medical Center, New York, New York

    Locations

    162 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT05580562 on ClinicalTrials.gov

12. Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

    Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT02800486 on ClinicalTrials.gov

13. Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

    The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatme…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00870129 on ClinicalTrials.gov